← Leaderboards
Francis Gigliotti
University Of Rochester
$9,264,116
Attributed
$10,282,255
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–20$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$17,696,207 · 11
By mechanism
R01$8,026,207 · 4
P01$7,413,952 · 1
T32$2,186,994 · 1
M01$69,054 · 5
Top collaborators
- Terry W Wright6 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Terry W Wright$11,076,508
- Martin S Zand$41,716,435
- Jacqueline Abranches$2,207,030
- Robert C Rose$2,700,195
- Barry R Stripp$21,504,437
Others in their field
Top investigators on “Pneumocystis Carinii”
- Jay K Kolls · Tulane University Of Louisiana$15,992,638
- Judith E Feinberg · University Of Cincinnati$12,549,831
- Andrew H Limper · Mayo Clinic Coll Of Medicine, Rochester$12,262,969
- Umesh G Lalloo · University Of Kwazulu-Natal$10,670,670
- Melanie T Cushion · Cincinnati Va Medical Center Research$9,123,638
- Terry W Wright · University Of Rochester$8,891,828
Research focus
Pneumocystis CariniiLung InjuryMediatingAntigensProductionPneumoniaImmuneActive ImmunizationInflammationPneumocystis PneumoniaMolecularImmunosuppressedCellsMouse ModelPassive ImmunizationImmune SystemImmunocompromised HostLeadInfectionAntibioticsBasic ScienceImmune ResponseEnvironmentCharacteristics
Grant awards (52)
Passive and Active Immunization for Pneumocystis$466,112
R01 · FY2020 · AI · contact PI
Passive and Active Immunization for Pneumocystis$466,112
R01 · FY2019 · AI · contact PI
Passive and Active Immunization for Pneumocystis$466,112
R01 · FY2018 · AI · contact PI
Passive and Active Immunization for Pneumocystis$465,229
R01 · FY2017 · AI · contact PI
Passive and Active Immunization for Pneumocystis$464,598
R01 · FY2016 · AI · contact PI
Training in Pediatric Infectious Diseases$172,751
T32 · FY2014 · AI · contact PI
Training in Pediatric Infectious Diseases$183,974
T32 · FY2013 · AI · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$385,000
R01 · FY2012 · HL · contact PI
Training in Pediatric Infectious Diseases$115,539
T32 · FY2012 · AI · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$112,359
R01 · FY2012 · HL · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$385,000
R01 · FY2011 · HL · contact PI
Training in Pediatric Infectious Diseases$98,840
T32 · FY2011 · AI · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$385,000
R01 · FY2010 · HL · contact PI
Training in Pediatric Infectious Diseases$142,356
T32 · FY2010 · AI · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$385,000
R01 · FY2009 · HL · contact PI
Monoclonal Antibodies for the Study of P. carinii$362,764
R01 · FY2009 · AI · contact PI
Training in Pediatric Infectious Diseases$167,145
T32 · FY2009 · AI · contact PI
Training in Pediatric Infectious Diseases$55,762
T32 · FY2009 · AI · contact PI
Monoclonal Antibodies for the Study of P. carinii$6,608
R01 · FY2009 · AI · contact PI
P. carinii Pneumonia Lung Damage: CD8-driven Cellular and Molecular Events$383,920
R01 · FY2008 · HL · contact PI
Monoclonal Antibodies for the Study of P. carinii$362,764
R01 · FY2008 · AI · contact PI
Training in Pediatric Infectious Diseases$172,884
T32 · FY2008 · AI · contact PI
Monoclonal Antibodies for the Study of P. carinii$369,544
R01 · FY2007 · AI · contact PI
Training in Pediatric Infectious Diseases$158,576
T32 · FY2007 · AI · contact PI
Lung Damage from P. carinii: pathogenesis and prevention$1,520,630
P01 · FY2006 · HL · contact PI
Monoclonal Antibodies for the Study of P. carinii$377,375
R01 · FY2006 · AI · contact PI
Training in Pediatric Infectious Diseases$117,122
T32 · FY2006 · AI · contact PI
Lung Damage from P. carinii: pathogenesis and prevention$1,514,791
P01 · FY2005 · HL
Monoclonal Antibodies for the Study of P. carinii$383,164
R01 · FY2005 · AI
Training in Pediatric Infectious Diseases$110,257
T32 · FY2005 · AI
PACTG P1038 PHASE I/II STUDY HIGH DOSE LPV/R WITH/WITHOUT SQV IN HIV+ SUBJECTS$10,526
M01 · FY2005 · RR
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV+ &HIV- CHILDREN$4,511
M01 · FY2005 · RR
Lung Damage from P. carinii: pathogenesis and prevention$1,485,065
P01 · FY2004 · HL
TRAINING IN PEDIATRIC INFECTIOUS DISEASES$117,887
T32 · FY2004 · AI
Lung Damage from P. carinii: pathogenesis and prevention$1,443,828
P01 · FY2003 · HL
MONOCLONAL ANTIBODIES FOR THE STUDY OF P CARINII$329,030
R01 · FY2003 · AI
TRAINING IN PEDIATRIC INFECTIOUS DISEASES$116,449
T32 · FY2003 · AI
Lung Damage from P. carinii: pathogenesis and prevention$1,449,638
P01 · FY2002 · HL
MONOCLONAL ANTIBODIES FOR THE STUDY OF P CARINII$319,447
R01 · FY2002 · AI
TRAINING IN PEDIATRIC INFECTIOUS DISEASES$165,727
T32 · FY2002 · AI
ACTG 377:PRAM2: PH I &II RM,MC,COMPARING 4 ANTIRETROVIRAL AGENTS PRO$0
M01 · FY2002 · RR
ACTG 338--A PHASE II(PRAM) OF NOVEL ANTI RETROVIRAL THERAPY IN STABLE EXPERIENCE$0
M01 · FY2002 · RR
MONOCLONAL ANTIBODIES FOR THE STUDY OF P CARINII$310,141
R01 · FY2001 · AI
P CARINII PNEUMONIA--IMMUNOPATHOGENESIS OF LUNG INJURY$271,550
R01 · FY2001 · HL
TRAINING IN PEDIATRIC INFECTIOUS DISEASES$149,083
T32 · FY2001 · AI
ACTG 338--A PHASE II(PRAM) OF NOVEL ANTI RETROVIRAL THERAPY IN STABLE EXPERIENCE$19,613
M01 · FY2001 · RR
COMPARATIVE STUDY OF ANTIRETROVIRAL THERAPY IN CHILDREN AND ADOLESCENTS$19,613
M01 · FY2001 · RR
MONOCLONAL ANTIBODIES FOR THE STUDY OF P CARINII$301,106
R01 · FY2000 · AI
P CARINII PNEUMONIA--IMMUNOPATHOGENESIS OF LUNG INJURY$268,272
R01 · FY2000 · HL
TRAINING IN PEDIATRIC INFECTIOUS DISEASES$142,642
T32 · FY2000 · AI
ACTG 338--A PHASE II(PRAM) OF NOVEL ANTI RETROVIRAL THERAPY IN STABLE EXPERIENCE$14,791
M01 · FY2000 · RR
ACTG 377:PRAM2: PH I &II RM,MC,COMPARING 4 ANTIRETROVIRAL AGENTS PRO$0
M01 · FY2000 · RR